Revenio's Crumpling Margins Are Largely a Deal Artifact — the Balance Sheet Is the Real Test

On September 8, Revenio Group (HEL: REG1V) reported a second quarter in which gross margin fell from 72.6% to 64.7% in a year, and investors knocked about 16% off the stock within hours. On its face that reads like a margin collapse. It is not. Most of the damage is mechanical — the arithmetic of a €290 million acquisition that closed in May and changed the shape of a Finnish eye-care group overnight. The honest way to judge this stock now is to separate that accounting noise from the parts that actually matter: a newly leveraged balance sheet and a legacy growth engine that has gone flat.

The crumple was mostly arithmetic

For years Revenio, maker of the iCare tonometer and imaging devices, ran as a high-margin, net-cash compounder. Then in April it agreed to buy France's Visionix, an ophthalmic-instrument maker, for a €290 million enterprise value, paid with €194 million in cash and €56 million in new shares. Two things followed mechanically. Revenio began consolidating a lower-margin business from June 1, which diluted the gross margin all on its own. On top of that, roughly €3.4 million of one-off acquisition costs sat in operating profit, while tariffs and component inflation added their own drag.

The reported numbers therefore look far worse than the underlying business did. Operating margin printed at just 6.1%, earnings per share at €0.02. Strip the non-recurring items and the adjusted operating margin came in at 14.6% — down from a year ago, but a collapse in the way the headline describes it.

What's not noise is the balance sheet

The real change is on the other side of the income statement. The old Revenio carried net cash; its gearing was negative at −1.3%. Funding the acquisition flipped that to net debt of €238 million, gearing of 159%, and an equity ratio that fell from 77% to 31%. As a ratio to adjusted EBITDA, debt now sits at about 5.3 times, the dividend is suspended, and an €80 million rights issue is planned for autumn to repay the bridge loan, aiming to bring leverage back to roughly 3 times. None of that is a reporting quirk. It is a genuine, credit-ratings-would-notice change in the risk profile of what an owner holds.

Then there is the part that matters most and is easiest to miss. Excluding Visionix, the original Revenio business was flat in the quarter, with softness blamed on Middle East and Asia demand. The compounding engine that justified the old 37 times earnings multiple has stalled.

The cash-flow path is the proof that hasn't arrived

This is where the framework matters. The market has already reset — hard. Full-year sales guidance was lifted to €190–205 million, but forward earnings estimates were slashed (consensus EPS roughly halved from €0.72 toward €0.38), and the trailing P/E has compressed from the mid-30s to about 22. The bar is low, in other words. The problem is that the underlying trajectory has not yet turned to support it.

Operating cash flow for the first half was negative at about −€6 million, versus +€11 million a year earlier. So this is not the clean setup where the numbers are already improving underneath and the market simply has not caught up. Here the business bought a bigger future with cash it is still burning. There is no forward free-cash-flow multiple to lean on, because free cash flow has not shown up yet; the case rests on whether it does.

Management says integration is running on or ahead of plan, that about a quarter of a targeted €20 million-plus EBITDA synergy stream is already secured, and that the combination expands the addressable market 2.5-times to over €2.5 billion. That is the bull path: after the rights issue takes leverage toward 3 times, the combined company starts throwing off cash against expectations that have already been marked down.

I can be wrong again — the payoff depends on a cash-flow path that is not yet visible. The test is concrete. If the deleveraged entity starts generating free cash flow over the next 12 months while legacy demand comes back, the reset is the opportunity and this drop is the entry. If free cash flow stays negative, synergies stall, and the original franchise keeps shrinking, then the selloff was correct, not just painful. That is the difference between the two, and it is checkable from the quarterly cash-flow statement rather than the margin line the headlines fixed on.